Citation Impact
Citing Papers
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
2008 StandoutNobel
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
2010
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy
2003
Large-Scale Production of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation*
1998
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes
1996
Vaccination with Dendritic Cells Inhibits the Growth of Hepatic Metastases in B6 Mice
1998
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
Renal-Cell Carcinoma
1996 Standout
Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
1995
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome
1991 Standout
Cancer vaccines based on the identification of genes encoding cancer regression antigens
1997
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
1999 StandoutNobel
Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
1998
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
2008
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
2015
Intratumoral LAK cell and interleukin-2 therapy of human gliomas
1989
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
1999
Cell-mediated cytotoxicity
1993 StandoutNobel
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Dendritic Cells In Vivo: A Key Target for a New Vaccine Science
2008 StandoutNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Neuroblastoma
2007 Standout
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
1988 Standout
Adoptive-cell-transfer therapy for the treatment of patients with cancer
2003
Staphylococcus aureusInfections
1998 Standout
Adoptive cell therapy for the treatment of patients with metastatic melanoma
2009
Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis
1994 StandoutScience
The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells.
1990
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.
1993 StandoutNobel
The Staphylococcal Enterotoxins and Their Relatives
1990 StandoutScience
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70
2000 StandoutNobel
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
1985
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Expansion of natural killer cells but not T cells in human interleukin 2/interleukin 2 receptor (Tac) transgenic mice.
1989 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.
1993
Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy
2004
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer
1986
Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
1985
Selective anergy of V beta 8+ T cells in human immunodeficiency virus-infected individuals.
1994 StandoutNobel
Convection-enhanced delivery of macromolecules in the brain.
1994 Standout
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials
1987
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001 StandoutNobel
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
1996
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients
2006
A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
1987 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
Tolerogenic Dendritic Cells
2003 StandoutNobel
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
1985 Standout
Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
2001 StandoutNobel
Dendritic Cells Exposed to Human Immunodeficiency Virus Type-1 Transmit a Vigorous Cytopathic Infection to CD4 + T Cells
1992 StandoutScienceNobel
Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced Cancer
1987
T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells
2002
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
1986
Exploiting the curative potential of adoptive T‐cell therapy for cancer
2013
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
The In Vitro Generation of Effector Lymphocytes and Their Employment in Tumor Immunotherapy
1983
The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2
1986
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999 StandoutNobel
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Interleukin-2: Inception, Impact, and Implications
1988 StandoutScience
Works of Cornelia Hyatt being referenced
Systemic administration of recombinant human interleukin-2 in mice.
1984
Growth of tumor‐infiltrating lymphocytes from human solid cancers: Summary of a 5‐year experience
1996
Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy
1987
NORMAL ADULT MURINE CELLS IN TISSUE CULTURE EXPRESS FETAL ANTIGENS
1977
Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
1985
Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy
1986
Lysis of Autologous Melanoma Cells by Tumor*Infiltrating Lymphocytes: Association With Clinical Response
1991